Eosinophil peroxidase is a valid biomarker of eosinophilic inflammation in asthma, and its measurement reveals how blood measures of eosinophilic inflammation can miss airway eosinophilic inflammation and how mepolizumab does not always normalize airway eosinophilic inflammation. This evidence concerns the gene EPX and asthma.